Modulation immunitaire : le nouveau traitement LDI

Comment lutter contre les multiples infections chroniques qui se développent en présence de produits toxiques dans le corps

Modulation immunitaire : le nouveau traitement LDI

Messagede un_ptit_gars » Mar 20 Oct 2015 07:18

Salut a tous,

Une nouvelle forme de traitement immunitaire est apparu sur le décors des "lymés" et semble etre très prometteur: le LDI (Low Dose Immunotherapy).

Ce traitement appartient a la grande famille des thérapies de "désensibilisation biologique" (car il existe aussi des désensibilisations énergétiques: NAET, Asyra pro, morathérapie, etc), dans la lignée de la micro-immunothérapie ou des désensibilisations courament utilisé en france (pollen, poil chat/chient, etc).
Cependant les "allergènes" employés, ainsi que la manière de réinformer le corps via cette technique semble etre (d'après les premiers retours disponibles sur le net) très prometteurs sur une large panel de maladies ou il y a une suractivation immunitaire et un cytokine storm (dont bien entendu lyme qui est en plein dedans), avec des taux de fortes améliorations qui semblent être très élevés (même si la prudence doit tjrs etre employé sur des chiffres et le recul nécéssaires sur du plus long terme).

Je vous copie colle ci dessous le début d'un très bon article, puis vous trouverez dans le fichier ci joint le détail des principes employés et la spécificité du LDI dans le cadre des maladies environementales comme les notres.
C'est un peu long, plutot technique, mais ça vaut la peine de s'y pencher dessus!

Pti gars
Rappel : Aucun message posté ici ne fait office de prescription médicale, seul le médecin traitant est habilité à prescrire un traitement- www.forum-melodie.fr/phpBB3/viewtopic.php?f=53&t=2869

Lisez l'e-book du forum! www.forum-melodie.fr/phpBB3/viewtopic.php?f=80&t=4197
Avatar de l’utilisateur
un_ptit_gars

Administrateur
Administrateur
 
Messages: 11110
Inscription: Ven 23 Nov 2007 07:00
Localisation: Toulouse

Re: Modulation immunitaire : le nouveau traitement LDI

Messagede un_ptit_gars » Mar 20 Oct 2015 07:20

ABSTRACT

Background: Conventional allergen-specific-immunotherapy (AIT) is a well-established treatment for a
variety of environmental allergies that involves the administration of gradually increasing doses of
allergen extracts over a period of years, given to patients by injection or sublingually. The effects of AIT
leads to decreased disease severity, less drug usage, prevention of future allergen sensitizations, and a
long-term curative effect. The aim of AIT is to induce long-term clinical tolerance against allergens,
leading this way to a decrease of the over-reactive immune response and subsequent inflammation,
both responsible for allergic symptoms. The induction of tolerance is mainly addressed by generation of
allergen-specific T regulatory cells (Tregs), interleukin-10 (IL-10) and transforming growth factor beta
(TGF-β); these key mediators promote the deviation of the chronic, established and pathologic
inflammatory immune profile towards a more tolerogenic and anti-inflammatory response (i.e., a more
proper balance among the responses Th1, Th2 and Tr1 is reached), thus ameliorating or eliminating the
symptomatology.

Aside from allergy, there is extensive literature on the effectiveness of certain heterogeneous variants of
the conventional AIT to treat a wide range of diseases in animals, and some positive reports in several
conditions in humans observed in phase II trials, including a variety of autoimmune conditions and some
chronic infectious diseases, such as multiple sclerosis, rheumatoid arthritis, Behcet’s disease,
inflammatory bowel diseases, or chronic HBV infection. However, this approach has yet to successfully
translate to the clinic in phase III trials. Key factors for this translation will include the finding of more
appropriate doses and routes of antigens (Ags) administration. There is not a standardized consensus on
how to implement conventional AIT to diseases other than allergy, what might account for the mixed
results observed so far. However, enzyme potentiated desensitization (EPD), low dose allergen therapy
(LDA), and low dose immunotherapy (LDI) constitute variants of AIT that are not only standardized, but
are also demonstrating encouraging results. Solid evidence has shown the effectiveness of EPD for a
greater number of conditions than AIT has, with virtually no side effects, and promoting much longer
lasting desensitization than conventional AIT. Compared with AIT, EPD uses much lower doses of Ags
and employs β-glucuronidase as an adjuvant enzyme to enhance the tolerization effect. On the other
1hand, as for the differences between EPD and LDA, although there are subtle differences between them,
they can be considered similar approaches in practical terms and therefore, it seems that the same
conditions which have shown to successfully respond to EPD, should as well improve with LDA. In the
same vein, LDI constitutes a new and cutting-edge variant of LDA which, by using a wider range of Ags
and more individualized doses, is exhibiting very hopeful results for many other non-allergic conditions.
However, no formal data about LDA or LDI has been yet published.

Objectives: Many autoimmune diseases are initially triggered, at least in part, by microbes. Well-known
examples of this, are the etiopathogenic links known to exist between proteus mirabilis microbes and
rheumatoid arthritis or between klebsiella pneumoniae and both ankylosing spondylitis and Crohn's
disease. In this context, LDI applied to autoimmune diseases and chronic infectious conditions, works
under the rationale that molecular mimicry-mediated autoimmunity is the main underlying cause of
their pathogenesis. Thus, under this paradigm, allergy may be considered as a failure of tolerance to
harmless environmental allergens, while autoimmunity could be conceived as a failure of tolerance to
self-Ags; therefore, as it is known to be possible to stop allergic reactions to environmental Ags through
reinstating tolerance with conventional AIT, or with other forms of specific-antigen-based-
immnotherapy, similarly, it should be plausible to do the same thing for certain autoimmune conditions
and chronic infectious diseases, by using self-Ags or the appropriate triggering agent. Under these
premises, the first goal of the current article is to compile evidence on how different approaches of AIT
seem to work for these conditions, and to determine which characteristics are shared by those diseases
which seem to successfully respond to these therapies. The final objective is to elucidate whether two
specific conditions, i.e., chronic Lyme disease (CLD) and myalgic encephalomyelitis / chronic fatigue
syndrome (ME/CFS), could be considered as good potential candidates to be treated with LDI.
Results: From the herein reviewed literature, it might be at least inferred that those conditions which
have shown to successfully respond to either of the different AIT approaches that use much larger doses
of Ags, might as well respond to LDA, including numerous autoimmune disorders, chronic inflammatory
conditions and chronic infectious diseases. Likewise, the successful results obtained from clinical trials
on EPD, could be extrapolated to some degree to LDI, taking into account the similarities between both
techniques. On the other hand, those conditions for which distinct types of AIT have shown to be of
benefit, share the following features: (1) chronic inflammatory conditions characterized by an ongoing
immune activation; (2) immune deviation from the phenotype that would otherwise properly address
the known/suspected trigger/s; (3) acquired molecular mimicry-mediated autoimmunity as an
important pathogenic mechanism; (4) symptomatology thought to be a result of the ongoing immune
activation, inflammation and related autoimmunity.

Conclusions: Although the relationship between CLD and ME/CFS has yet to be clarified, there are clear
and key overlapping features between these conditions. Besides, there is extensive and compelling
evidence showing that both CLD and ME/CFS are characterized by: (1) a state of ongoing immune
activation; (2) an immune deviation from that that would properly address the trigger/s, thought to play
a key role in the initiation and perpetuation of the condition; (3) autoimmune processes mediated by
either molecular mimicry, hyper responsive T and/or B cells, or antibodies complexes (these
autoimmune processes have shown in both conditions to be pathological and to correlate with the type
as well as with the severity of symptoms); (4) a general agreement in the fact that symptoms are the
direct result of the chronic inflammation and related autoimmunity. Taken all together, CLD and ME/CFS
seem to present the common pathophysiologic characteristics to be considered as potential candidates
to successfully be treated with LDI, thus corroborating the promising empirical results already reported
by many doctors and patients.

Doc intégral:
LDI for CFS and Lyme.17.10.2015.pdf
(975.36 Kio) Téléchargé 479 fois
Rappel : Aucun message posté ici ne fait office de prescription médicale, seul le médecin traitant est habilité à prescrire un traitement- www.forum-melodie.fr/phpBB3/viewtopic.php?f=53&t=2869

Lisez l'e-book du forum! www.forum-melodie.fr/phpBB3/viewtopic.php?f=80&t=4197
Avatar de l’utilisateur
un_ptit_gars

Administrateur
Administrateur
 
Messages: 11110
Inscription: Ven 23 Nov 2007 07:00
Localisation: Toulouse


Retourner vers Virus, bactéries, champignons, vers et autres parasites

Qui est en ligne

Utilisateurs parcourant ce forum: Aucun utilisateur enregistré et 5 invités